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Abstract
TRAIL (TNF-related apoptosis-inducing ligand) can selectively trigger apoptosis in various 
cancer  cell  types.  However,  many  cancer  cells  are  resistant  to  death  receptor-mediated 
apoptosis.  Combination  therapy  with  platinum  complexes  may  affect  TRAIL-induced 
signaling via modulation of various steps in apoptotic pathways. Here we show that cisplatin 
or  a  more  potent  platinum(IV)  complex  LA-12  used  in  twenty-fold  lower  concentration 
enhanced  killing  effects  of  TRAIL  in  human  colon  and  prostate  cancer  cell  lines  via 
stimulation  of  caspase  activity  and overall  apoptosis.  Both  platinum complexes  increased 
DR5 surface expression in colon cancer cells. siRNA-mediated DR5 silencing rescued cells 
from  sensitizing  effects  of  platinum  drugs  on  TRAIL-induced  caspase-8  activation  and 
apoptosis,  showing the functional importance of DR5 in the effects observed.  In addition, 
both cisplatin and LA-12 triggered the relocalization of DR4 and DR5 receptors to lipid rafts, 
and  accelerated  internalization  of  TRAIL,  which  may  also  affect  TRAIL  signaling. 
Collectively, modulations of the initial steps of the extrinsic apoptotic pathway at the level of 
DR5 and plasma membrane are important for sensitization of colon and prostate cancer cells 
to TRAIL-induced apoptosis mediated by LA-12 and cisplatin. 
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Introduction
The main goal of anticancer therapy is to selectively induce apoptosis in cancer cells 
while sparing untransformed cells and healthy tissues. One promising approach is triggering 
of  the  extrinsic  apoptotic  pathway  by  TRAIL  (tumor  necrosis  factor-related  apoptosis-
inducing ligand), a member of TNF superfamily, which has been shown to selectively induce 
apoptosis in various cancer cells in vitro and in vivo [1,2]. The different sensitivity/resistance 
to TRAIL in normal and cancer cells is still a matter of debates among the experts. Several 
potential ways of resistance of non-tumorigenic cells to TRAIL have been proposed so far, at 
the level of both surface and intracellular  molecules.  Furthermore,  many tumor cells have 
been shown to be resistant to the effects of TRAIL due to deficiencies in apoptotic pathways 
or over-activated pro-survival signaling [3-6]. Elucidation of the molecular mechanisms of the 
resistance,  and designing safe combination therapy using agents capable of sensitizing the 
cancer but not normal cells to TRAIL-induced apoptosis are important prerequisites of the 
successful clinical application of this cytokine. 
There are five known types of TRAIL receptors. Death receptors DR4 (TRAIL-R1) 
and DR5 (TRAIL-R2) containing death domain (DD) are responsible for transmission of the 
apoptotic signal, while decoy receptors DcR1 (TRAIL-R3, lacking DD) or DcR2 (TRAIL-R4, 
with truncated DD), and a soluble receptor osteoprotegerin (OPG, TRAIL-R5) are unable to 
signal apoptosis. However, the cell surface expression of particular TRAIL receptor may not 
fully  corelate  with  its  functional  importance  in  induction/inhibition  of  TRAIL  apoptotic 
signaling. It has been published in several cancer cell types that despite the presence of both 
DRs  at  their  surface,  particular  tumors  preferentially  signal  through  either  DR4  (e.g. 
lymphocytic leukemia) [7] or DR5 (e.g. colon cancer) [8]. The specific DR involvement as 
well as differences in apoptotic signaling mediated by DR4 or DR5 remain to be answered. 
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Some  authors  also  showed  a  higher  expression  of  decoy  receptors  in  non-tumorigenic 
compared to tumor cells.  However, this phenomenon may be tissue specific,  and the sole 
presence of surface decoy receptors has often been found not sufficient to protect the cells 
from apoptotic effect of TRAIL [9,10]. 
DR4 and  DR5  mediate  TRAIL-induced  apoptosis  by  recruiting  FADD  (Fas-
Associated  DD)  protein  and  pro-caspase-8  to  form  a  death-inducing  signaling  complex 
(DISC). The amount of caspase-8 activated at the DISC is important factor affecting further 
progression of apoptotic signaling. In so-called type I cells, abundantly activated caspase-8 
directly cleaves and activates effector caspases, which leads to execution of cell death. In type 
II cells, the amount of caspase-8 activated at the DISC is not sufficient to trigger an adequate 
effector caspase stimulation; therefore, amplification of the apoptotic signal via mitochondria 
is required [11,12]. In this case, a BH-3-only protein Bid is cleaved by caspase-8 to tBid, and 
translocated to mitochondria to trigger processes leading to release of proapoptotic proteins 
such as cytochrome c into the cytosol [12]. Cytochrome c, Apaf-1, and procaspase-9 then 
form  an  apoptosome  complex  where  caspase-9  is  activated,  and  the  apoptotic  signal  is 
augmented.
The initial  steps  of  TRAIL signaling have been studied  intensively,  especially  the 
regulation  of  TRAIL  receptor  expression,  their  translocation  to  the  cell  surface,  plasma 
membrane distribution, lipid raft (co)localization, and receptor internalization (endocytosis). 
Lipid  rafts  are  dynamic  plasma  membrane  microdomains  enriched  with  cholesterol  and 
sphingolipids. They play fundamental roles in diverse cellular processes, particularly in signal 
transduction, by promoting compartmentalization of membrane proteins and lipids [13,14]. 
Recent studies have suggested the role of lipid rafts as platforms for DR-mediated apoptosis 
signaling [15]. Relocalization of TRAIL DRs into the lipid rafts has been shown to facilitate 
DISC formation and caspase-8 activation-initiated apoptosis, while TRAIL-DISC assembly in 
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the non-raft phase of the plasma membrane resulted in inhibition of caspase-8 cleavage, and a 
promotion of antiapoptotic signaling [15]. Changes of the DRs distribution within the plasma 
membrane may therefore have a crucial impact on modulation of cell sensitivity/resistance to 
apoptotic signals triggered by TRAIL. Death ligand/receptor interactions may induce receptor 
clustering and internalization, which targets the active receptor to endocytic compartments. 
An  essential  requirement  for  receptor  internalization  in  transmitting  the  CD95L-induced 
apoptotic signal has been reported [16,17]. In contrast, although being rapidly internalized, 
TRAIL and its DRs have been reported not to essentially require internalization for DISC 
formation, caspase-8 activation, and subsequent apoptosis induction in BJAB type I cells [18]. 
Combined  treatment  with  chemotherapeutic  drugs  has  been  shown  to  overcome 
TRAIL  resistance  in  many  cancer  cell  types.  Diverse  molecular  mechanisms  have  been 
reported to be responsible for synergistic effects of these agents to induce apoptosis of target 
cells. Chemotherapy may have a great impact on the crucial steps of the TRAIL signaling 
pathway,  e.g.  through increase  of  TRAIL DR expression  [19,20],  lipid  raft  relocalization 
[21,22],  decrease  of  cFLIP protein  level  [23],  facilitating  DISC formation  and  caspase-8 
activation [24], upregulation/downregulation of proapoptotic/antiapoptotic molecules [25], or 
stimulation of mitochondria [26]. The involvement of the particular events depends on the 
type and/or stage of cancer,  type I/II cells,  and the type of the selected chemotherapeutic 
drug(s).
Platinum complexes,  e.g.  cisplatin,  carboplatin  and oxaliplatin,  belong to  the most 
widely used chemotherapeutic agents in the treatment of solid cancers. By creating covalent 
bonds with DNA, they induce DNA damage signaling, which leads either to cell cycle arrest 
providing time to repair the damage, or immediate activation of apoptotic signaling via the 
intrinsic mitochondrial pathway, and killing of cancer cells. However, application of therapy 
using  platinum  drugs  such  as  cisplatin  is  limited  due  to  serious  side  effects  and/or 
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development of intrinsic or acquired resistance of the cancer cells. In the past two decades, 
plenty of newly synthesized analogues of platinum complexes were examined, and some of 
them  entered  the  clinical  trials,  e.g.  Pt(IV)  complexes.  LA-12  is  a  novel  Pt(IV) 
adamantylamine ligand-containing complex, currently in phase I of clinical trials. It has been 
shown to be more cytotoxic than satraplatin and to efficiently induce cell death in a panel of 
14 cancer cell lines with various sensitivity to cisplatin [27] and in ovarian carcinoma cells 
with acquired (A2780cis) or intrinsic resistance to cisplatin (SK-OV-3) [28,29]. LA-12 has 
been shown to induce cell cycle arrest and apoptosis in various cancer cells [30,31,32,33].
 In vivo studies in murine xenografts revealed a higher antitumor activity of LA-12 
compared to cisplatin and Pt(IV) complex satraplatin, and enhanced tissue penetration, and 
lower  acute  systemic  toxicity.  Due  to  its  improved  lipophilicity,  LA-12  was  shown  to 
effectively penetrate  tissues and tumors  and can be administered perorally [34-36].  Taken 
together, these data imply that LA-12 is a promising candidate for cancer therapy, with high 
effectivity in killing cancer cells in vitro and in vivo and low toxic side effects in vivo.
In  the present  study,  we investigated  the  role  of  a  novel  platinum drug LA-12 in 
modulating  colon  and  prostate  cancer  cell  sensitivity  to  apoptotic  effects  of  TRAIL,  and 
compared the LA-12-mediated effects with those exerted by conventionally used cisplatin in 
combination with TRAIL. The molecular  mechanisms responsible for the enhancement  of 
apoptosis following combined treatments with these agents were investigated, with special 
focus on the most upstream events of the TRAIL signaling pathway, namely TRAIL DRs and 
initiator caspase-8. Both platinum complexes increased DR5 surface expression and lipid raft 
localization, and consequentially TRAIL-induced caspase-8 activation and apoptosis, which 
could  be  counteracted  by  siRNA-mediated  DR5  silencing.  Our  results  demonstrate  that 
modulating the initial steps of the extrinsic apoptotic pathway by LA-12 and cisplatin at the 
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level of DR5 and plasma membrane are important events in sensitization of colon and prostate 
cancer cells to TRAIL-induced apoptosis. 
Materials and methods
Materials and reagents
The  stock  solutions  of  cisplatin  (cis-diamminedichloroplatinum(II);  FW  300.1)  (Sigma-
Aldrich  Corp.;  St.  Louis,  MO,  USA);  and  LA-12  ([(OC-6-43)-bis(acetato)(1-
adamantylamine)ammine  dichloroplatinum(IV)];  FW  552.4)  (Pliva-Lachema,  a.s.;  Brno, 
Czech  Republic) were  freshly  prepared  before  use. Human  N-terminally  His-tagged 
recombinant Apo2L/TRAIL (amino acids 95–281) was affinity-purified from cell lysates of 
the producer bacteria  (E. coli,  strain BL-21) and contaminating bacterial  endotoxins  were 
removed by Endotrap chromatography (Profos AG) [37].
Cell culture
The human colon adenocarcinoma cell line HCT-116 (obtained from Prof. B. Vogelstein) and 
prostate  cancer  PC-3 (from ATCC) epithelial  cell  lines  were  maintained  in  McCoy’s  5A 
modified medium with 1.5 mM L-glutamine (Sigma-Aldrich; St. Louis, MO, USA) or F12, 
respectively,  supplemented with penicillin  (100 U/ml) and streptomycin (0.1 mg/ml) (both 
Duchefa  Biochemie;  The  Netherlands),  sodium  bicarbonate  (1.5  g/l, Serva;  Heidelberg, 
Germany),  and  10% heat-inactivated  fetal  bovine  serum (HCT-116)  or  10% fetal  bovine 
serum (PC-3) (PAA Pasching, Austria). The cells were incubated in a humidified incubator at 
37 °C in a 5% CO2 atmosphere,  and passaged twice a week by EDTA/PBS washing and 
trypsinization.
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WST cytotoxicity assay
HCT-116 and PC-3 cells were seeded in 96-well plates in a density of 20,000 cells per cm2. 
After 24 h (HCT-116) or 48 h (PC-3), the cells were treated with cisplatin (10 μM) or LA-12 
(0.5 μM). Twenty-four hours later, various amounts of TRAIL (6.25-100 ng/ml) were added. 
After  24  h  of  incubation,  tetrazolium  salt  WST-1  with  1-methoxy-5-methylphenazium 
methylsulphate (Serva; Heidelberg, Germany) was added for 4 h, and absorbance of a soluble 
formazan compound formed by metabolically active cells was analyzed using a microplate 
reader FLUOSTAR Galaxy (BMG Labtechnologies GmbH, Offenburg, Germany).
Real-time cell impedance analysis
Acea E-plates® 96  and an xCELLigence RTCA SP system including RTCA Software v1.2 
(both Roche; Applied Science, Prague, Czech Republic) monitors cellular events including 
cell  number,  adhesion,  viability,  and  morphology,  and  provides  information  about  the 
biological status of the cells in real time by measuring electrical  impedance across micro-
electrodes integrated on the bottom of its special tissue culture plates [38]. First, a standard 
background measurement was performed using 100 µl of complete culture media. PC-3 cells 
were  trypsinized,  counted,  and  seeded  in  additional  100  µl  of  culture  media  in  a  final 
concentration of 30,000 cells per cm2. The cells were monitored continually every hour after 
the seeding for a period of 48 h. Next, the cells were pretreated with cisplatin or LA-12 for 24 
h followed by treatment with TRAIL (HCT-116 cells: 100 ng/ml, PC-3 cells: 12.5 ng/ml) for 
another 20 h. During TRAIL treatment, the cells were monitored continually every 2 min in 
the  first  3  h,  and  then  every  30  min.  Acea  E-plates®  16  and  xCELLigence  RTCA  DP 
Analyzer were used for monitoring the effects of tested compounds after transfection with 
nontargeting siRNA (sc-37007) or siRNA targeting DR5 (sc-40237; both Santa Cruz; CA, 
USA). Briefly, HCT-116 cells were seeded in 200 µl of cultivation media without antibiotics 
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in a final concentration of 50,000 cells per cm2 and after overnight incubation the cells were 
transfected with control or DR5 siRNA using LipofectamineTM 2000 (Invitrogen; Carlsbad, 
CA,  USA)  according  to  the  manufacturer’s  instructions.  Twenty-four  hours  later,  the 
cultivation medium was replaced by a fresh one with penicillin/streptomycin and the cells 
were  treated  with  LA-12 (0.5  μM) for  24 hours.  Finally,  TRAIL (50 ng/ml)  was  added. 
During TRAIL treatment, the cells were monitored continually every 2 min for 4 hours. 
Flow cytometric analysis of TRAIL receptors on the cellular surface
After 24 h of incubation with cisplatin (10 μM) or LA-12 (0.5 μM), the attached cells were 
harvested  by gentle  trypsinization,  washed twice  in  cold  PBS with  0.2% BSA,  and then 
incubated with anti-DR4 (#HS101, 1:100), anti-DR-5 antibody (#HS201, 1:100; both FITC-
conjugated;  Alexis  Biochemicals  Corporation;  Lausen,  Switzerland)  or  anti-DR4  (anti-
CD261,  #1P-403-C025)  and  anti-DR5  (anti-CD262,  #1P-461-C025;  both  PE-conjugated, 
Exbio; Vestec, Czech Republic) on ice in the dark for 45 min. The cells were washed twice, 
and 7-AAD or LIVE/DEAD® Fixable Dead  Cell Stain Far Red (Invitrogen; Carlsbad, CA, 
USA) were added.  After  20 min,  the expression of DR4 and DR5 was assessed by flow 
cytometry (FACSCalibur, Becton Dickinson; San Jose, CA). CellQuestPro software was used 
for  data  acquisition  and  analysis.  Dead  cells  (7-AAD or  Dead  Cell  Stain  positive)  were 
excluded from analysis. Receptor expression on the cellular surface was expressed as a ratio 
of  the median  fluorescence index (MFI) of  the specific  antibody and MFI of the isotype 
control antibody.  To minimize the possibility of antibody-receptor complex internalization 
during the incubation  period,  we performed a staining  protocol  based on only 10 min  of 
incubation with both antibody and viability probe together. Both analyses gave similar results. 
 
Internalization of TRAIL
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TRAIL  was  labeled  using  Alexa  Fluor  647  Microscale  Protein  Labeling  Kit  (A3000, 
Molecular probes; Eugene, Oregon, US) based on the manufacturer’s instructions. Cells were 
seeded in a 12-well plate, incubated with cisplatin (10 μM) or LA-12 (0.5 μM) for 24 h, and 
then with Alexa Fluor 647-conjugated TRAIL for 5, 10, 20 or 30 min. Sucrose (0.25 M) was 
added at the same time to inhibit endocytosis of TRAIL. The plates were rapidly chilled on 
ice to stop internalization. The cells were washed in HEPES twice and incubated in a mixture 
of 0.2 M acetic acid and 0.2 M NaCl for 5 min on ice. After three washing steps in HEPES, 
the cells were incubated in EDTA/PBS and briefly trypsinized. Trypsin was neutralized by 
2% BSA in PBS. The cells were centrifuged, resuspended in 2% BSA, stained with propidium 
iodide (5 μg/ml), and immediately analyzed by flow cytometer [18]. The data were analyzed 
using CellQuest software. Doublets, debris and dead cells (propidium iodide positive) were 
excluded from analysis.
Western blot analysis
The  cells  were  harvested,  washed  twice  in  cold  PBS,  and  lysed  in  1% SDS buffer  and 
Western  blot  analysis  was  performed  as  previously described [30].  Immunodetection  was 
carried out with the following antibodies: anti-DR5 (1:1000, 210-743, Alexis, Biochemicals 
Corporation;  Lausen,  Switzerland),  caspase-8 (1:500, 9746, Cell  Signaling;  Danvers,  MA, 
USA), caspase-3 (1:500, sc-7272), PARP (1:500, sc-7150), lamin B (1:500, sc-6217) (all of 
them Santa Cruz, CA, USA), anti-DR4 (D3813, 1:500) and β-actin (A5441, 1:5000) (both 
Sigma-Aldrich Corp.; St. Louis, MO, USA). Densitometric quantification of the visualized 
bands  was  performed  by  ImageJ  software  (NIH,  Bethesda,  MD)  and  normalized  to  the 
expression of β-actin.
RNA isolation and real-time RT-PCR
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Total  RNA was  isolated  using  a  High Pure  RNA Isolation  Kit  (Roche  Applied  Science, 
Prague, Czech Republic)  according to the manufacturer’s instructions.  The sequences of a 
gene-specific primer for combination with Universal ProbeLibrary probes: DR5 (GenBank: 
AF012628.1), F: 5’-AGA GCC AAC AGG TGT CAA CAT; R: 5’-GCC TCC TCC TCT 
GAG ACC TT (probe #29, 04687612001); POLR2A (polymerase (RNA) II (DNA directed)) 
polypeptide  F:  5′-ATCTCTCCTGCCATGACACC-3′,  R:  5′-
AGACCAGGCAGGGGAGTAAC-3′  (probe  #1,  04684974001,  Roche Diagnostics  GmbH, 
Mannheim, Germany). The amplification reactions were carried out in a final volume of 20 μl 
in a reaction mixture containing 10  μl of QuantiTect Probe RT-PCR Master Mix, 0.2  μl of 
QuantiTect RT Mix (Qiagen; Valencia, CA, USA), 2 μl of solution of primers and probe, 5.8 
μl of water, and 2 μl of RNA sample. The final concentration of each primer was 0.4 μM and 
the probe was 0.1 μM. The amplifications were run on the RotorGene3000 with RotorGene 
Real-Time  Analysis  Software  (Corbett  Research;  Sydney,  Australia),  using  the  following 
program: 50 °C for 30 min for reverse transcription and 95 °C for 15 min for denaturation of 
cDNA,  followed  by  cycling  (40  repeats)  94  °C  for  15  s  and  60  °C  for  60  s  acquiring 
fluorescence. All PCR reactions were performed in triplicates and changes in gene expression 
were  calculated  using  the  comparative  threshold  cycle  method  [39]  with  POLR2A  as  a 
normalizing gene.
Immunofluorescent labeling TRAIL receptors and lipid rafts
PC-3 and HCT-116 cells were seeded in IBIDI 8-well coverslip chambers. The cells were 
washed three times in ice-cold HEPES buffer and incubated with 15 μg/ml anti-DR4 (MA1-
19025)  or  anti-DR5  (MA1-19416,  Affinity  Bioreagents;  Golden,  CO,  USA)  monoclonal 
antibodies  for  10 min  on ice.  After  three  washes,  Alexa  Fluor  488-conjugated  secondary 
antibody (A-11017, Molecular Probes, OR, USA) was added at 10 μg/ml together with 4 μg/
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ml Alexa Fluor 647-conjugated cholera toxin B-subunit  (C-34778, Molecular Probes, OR, 
USA) for 10 min on ice. After three washes, the cells were fixed with 4% formaldehyde and 
mounted  with  Mowiol  4-88  (Calbiochem). The  Cholera  toxin  B  subunit  binds  to  GM1 
glycosphingolipid rich domains and serves as one of the most widely used markers for lipid 
rafts.
Confocal laser scanning microscopy (CLSM) 
CLSM (Zeiss LSM 510) was used for colocalization measurements.  Alexa Fluor 488 was 
excited at 488 nm, and Alexa Fluor 647 was excited at 633 nm. Their fluorescence emission 
was detected through 505- to 550-nm band-pass and 650-nm long-pass filters, respectively. 
The images were taken in multitrack mode to completely exclude channel cross-talk (although 
the great spectral separation minimized this already). 512 × 512-pixel, 1.5  μm thick optical 
sections were obtained with a 40× C-Apochromat water immersion objective (NA=1.2).
Determining colocalization from image cross-correlation 
Colocalization of molecules at the few-hundred-nm scale was determined from CLSM images 
of double-labeled cells.  The optical  section was taken from the top horizontal  slice of the 
membrane  of  adherent  cells.  The  images  were  gated  on  the  presence  (above-background 
intensity)  of  at  least  one  of  the  fluorophores.  For  a  pair  of  images,  x and  y,  the  cross-
correlation  coefficient  between  the  intensity  distributions  of  cell-surface  labeling  was 
calculated as (1),
[1]
where xij and yij are fluorescence intensities at pixel coordinates i, j in images x and y, and x , 
y  are the mean intensities in each channel. The theoretical maximum is  C = 1 for identical 
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images and a value of 0 implies independent random localization of the labeled molecules. A 
custom program was written in LabView to analyze  the images.  The average intensity of 
labels in the membrane was also evaluated by the program [13,14].
RNA interference
HCT-116 cells  were  seeded at  a  density  of  20,000 cells  per  cm2 and  cultured  for  12  h. 
Transfections  were  carried  out  in  McCoy’s  medium  without  antibiotics  using  a 
LipofectamineTM 2000 transfection reagent (Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s  protocol.  The  small  interfering  RNA (siRNA) targeting  DR5 (40  nM; sc-
40237)  or  nontargeting  control  siRNA (40nM; sc-37007;  Santa  Cruz Biotechnology;  CA, 
USA) was added directly to the transfection reagent solution and incubated for 24 h. After the 
transfection, the medium was replaced by McCoy’s medium. 
Caspase activity assay
The cells were collected and caspase activity assay was performed as described previously 
[40]  using  fluorogenic  caspase-8  substrate  Ac-IETD-AMC  (ALX-260-042-M005,  Alexis, 
Biochemicals Corporation, Lausen, Switzerland).
Statistical analysis
The data were expressed as means ± S.D., and analyzed by ANOVA followed by a Tukey test 
or by a nonparametric Mann-Whitney U-test.  A  P value of less than 0.05 was considered 
significant. All statistical analyses were performed by the Statistica for Windows software, V. 
6.1 (StatSoft, Inc., Tulsa, OK, USA).
Results
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LA-12 or cisplatin enhanced cytotoxic effects of TRAIL in HCT-116 and PC-3 cell lines
After pretreatment with cisplatin (10 μM) or LA-12 (0.5 μM), the cytotoxic effects of TRAIL 
(6.25 – 100 ng/ml) were significantly enhanced as demonstrated by a decrease of HCT-116 
and PC-3 cell metabolic activity (WST test; Figure 1a, b and e, f). Platinum drug-mediated 
sensitizing effects were clearly evident already when combined with the lowest concentration 
of TRAIL (6.25 ng/ml). Using a real time impedance analysis (system xCELLigence; Figure 
1  c,  d  and  g,  h),  we  also  demonstrated  a  significant  decrease  of  cell  surface  adhesion 
following the combined treatment with cisplatin/LA-12 and TRAIL in both cell lines. The 
pretreatment with platinum drugs prevented recovery of the cell index value observed in cells 
treated with TRAIL alone. 
LA-12- or cisplatin-mediated potentiation of TRAIL-induced cytotoxicity is associated with  
activation of the apoptotic caspase cascade
In order to examine whether the cytotoxicity induced by combination of platinum drugs and 
TRAIL occurred via activation of the caspase cascade and apoptotic signaling, analysis of the 
cleavage  of  caspase-8,  -3,  and  effector  caspase  substrate  PARP was  performed  (Western 
blotting). Pretreatment with cisplatin or LA-12, followed by TRAIL, resulted in a substantial 
potentiation of specific processing of pro-caspase-8, -3, and PARP in HCT-116 cells (Figure 
2a) compared to TRAIL alone-treated cells. A similar increase in cleavage of pro-caspase-8 
and  -3  was  also  observed  in  PC-3  cells  following  combined  treatments  (Figure  2b).  A 
corresponding significant increase in the number of cells with characteristic apoptotic changes 
of  nuclear  morphology  (condensation  and  fragmentation  of  chromatin,  fluorescence 
microscopy) was also detected in cisplatin/LA-12 and TRAIL-treated cells compared to the 
agents used alone (data not shown).
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LA-12 and cisplatin were responsible for significant increase of surface DR5 expression in  
HCT-116 but not in PC-3 cells
LA-12 or cisplatin induced a significant concentration-dependent upregulation of the surface 
DR5 but not DR4 level in HCT-116 cells (Figure 3a). Increased surface expression of DR5 
following  treatment  with  platinum  drugs  in  HCT-116  was  also  confirmed  by  confocal 
microscopy (data not shown). No significant effects of any platinum drug in concentrations 
used on DR4 and DR5 surface  levels  were detected  in  PC-3 cells  using  flow cytometric 
analysis (Figure 3b). LA-12-mediated changes of DR5 surface level in HCT116 cells were 
accompanied by an increase in DR5 mRNA (Figure 3c) and total protein level (Figure 3d). 
Similarly, cisplatin enhanced amounts of DR5 mRNA (Figure 3c) and total protein (Figure 
3d) in HCT-116 cells. None of the two platinum complexes modulated total amount of DR4 
protein in HCT-116 cells (Figure 3d). 
Lipid raft  localization  of DR4 and especially  of  DR5 was increased upon treatment  with  
cisplatin derivatives
To determine the membrane domain localization of DR4 and DR5 with respect to lipid rafts, 
the receptors  on the cell  surface were labeled  with indirect  immunofluorescence  (specific 
monoclonal primary antibodies followed by Alexa Fluor 488 secondary Abs) and CTX B was 
used as a lipid raft marker specific to GM1 rich domains. The extent of colocalization was 
quantitated  by calculating  the Pearson’s correlation  coefficient  from confocal  microscopic 
optical  sections  of  upper  horizontal  membrane  layers  from  numerous  single  cells.  Both 
TRAIL DR4 and DR5 receptors colocalized with GM1 rich domains in the plasma membrane 
of PC3 as well as HCT-116 cells. An example is shown for DR5 in HCT-116 cells (Figure 4a, 
b,  c).  After 1h of cisplatin  or LA-12 treatment,  the colocalization between lipid rafts and 
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TRAIL receptors increased in both HCT-116 (Figure 4d) and PC-3 cells (Figure 4e). This 
effect was more pronounced for DR5. 
Cisplatin induced an increase of TRAIL internalization in both PC-3 and HCT-116 cell lines,  
while LA-12 was only effective in the latter one 
Following  treatment  with  TRAIL,  an  acute  time-dependent  increase  of  dye-conjugated 
TRAIL internalization was detected in both HCT-116 and PC-3 cell lines by flow cytometry. 
Suppression of TRAIL internalization by sucrose was used as a negative control of clathrin-
dependent endocytosis [18]. Pretreatment with cisplatin resulted in a significant enhancement 
of TRAIL internalization, starting from 10 or 20 min of subsequent TRAIL treatment in PC-3 
or  HCT-116  cells,  respectively  (Figure  5a,  b).  LA-12-mediated  stimulation  of  TRAIL 
internalization was detected only in HCT-116 cells following 30 min incubation with TRAIL 
(Figure 5b).
LA-12 or cisplatin-mediated increase of DR5 is essential for potentiation of TRAIL-induced 
caspase-8 activation and apoptosis in HCT-116 cells
To  determine  the  functional  role  of  DR5  in  the  LA-12/cisplatin  and  TRAIL-induced 
apoptosis, the expression of DR5 was down-regulated using specific siRNA. Transfection of 
HCT-116 cells with DR5 but not control siRNA resulted in a significant decrease of basal (72 
%) as well as LA-12/cisplatin-induced (78/80 %) surface level of DR5 (Figure 6a). Following 
DR5 siRNA transfection, LA-12/cisplatin-mediated stimulation of TRAIL-induced caspase-8 
processing/activation  and  apoptosis  (demonstrated  by  PARP  and  lamin  B  cleavage)  was 
significantly reduced (Figure 6b, c) compared to control siRNA-transfected cells. To further 
elucidate the role of DR5 in LA-12/cisplatin enhanced TRAIL-mediated cell death, the cell 
index  was  assessed  using  the  xCELLigence  system  (Figure  6d).  Silencing  of  DR5 
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significantly rescued the reduction of the cell index observed in TRAIL- and LA-12/TRAIL-
treated cells.  The results imply that cisplatin- or LA-12-mediated enhancement of TRAIL-
induced cell death depends on DR5 function. 
Discussion
The  ability  to  induce  apoptosis  in  tumor  cells  while  sparing  nontransformed  cells 
designates TRAIL for the therapy of cancer diseases. Unfortunately, an increasing number of 
studies demonstrate that many primary tumors are resistant to TRAIL monotherapy [41]. A 
promising  strategy  to  overcome  the  resistance  of  cancer  cells  and  improve  the  clinical 
outcome is represented by combination therapy. By this time, combinations of TRAIL with 
many other antitumor agents with various mechanisms of action including DNA damage have 
been tested [42,43]. However, detailed description of the molecular mechanisms of combined 
effects of these compounds has to precede their possible clinical application. Chemotherapy-
mediated enhancement of TRAIL toxicity in tumor cells has been shown to be regulated at 
many levels, e.g. TRAIL receptors expression and localization, DISC components expression 
and  modulation  of  their  assembly,  integrity  of  mitochondria,  prosurvival,  and  apoptotic 
signaling. Interactions of extrinsic and intrinsic pathways of apoptosis may also be profitable 
for  the  killing  of  type  II  cells  as  they rely on the mitochondrial  loop to  activate  enough 
effector  caspases  and commit  TRAIL-mediated  programmed cell  death.  In  our  study,  we 
showed that pretreatment with subtoxic concentrations of cisplatin and novel Pt(IV) complex 
LA-12  significantly  enhanced  TRAIL-induced  apoptosis  in  human  colon  and  prostate 
carcinoma cells, and we studied molecular mechanisms responsible for the observed effects.
Cisplatin has been shown to enhance the killing capacity of TRAIL in several cancer 
cell lines in in vitro [19,20,44,45], in vivo [46,47], and in ex vivo models [48]. Contradictory 
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studies demonstrating a cisplatin-mediated inhibition of TRAIL-induced cell death through 
direct inactivation of caspases have also been reported. The authors explain the discrepancy in 
their results compared to the majority of literature by the dependance on the duration of the 
treatment  [49,50].  In  our  study,  cisplatin  was  responsible  for  significant  potentiation  of 
TRAIL-induced apoptosis in human prostate and colon cancer cell lines. Importantly, similar 
effects  on  TRAIL-induced  apoptosis  were  also induced by novel  Pt(IV)  complex  LA-12, 
although a twenty-fold lower dose of LA-12 was used compared to cisplatin. The ability of 
LA-12 to  be effective  in  significantly  lower doses  when compared  to  other  conventional 
therapeutic  drugs,  together  with  its  favorable  pharmacokinetic  profile,  make  LA-12  a 
promising candidate for combination cancer therapy.  Enhancement of cell  death induction 
following cisplatin/LA-12 and TRAIL was confirmed by cytotoxic tests, the state-of-the-art 
noninvasive real time cell impedance analysis method, and biochemical and morphological 
apoptosis assays. 
The  death  domain-containing  receptors  DR4 and  DR5 are  important  mediators  of 
TRAIL  proapoptotic  signaling.  Modulation  of  their  surface  expression  may  affect  the 
apoptotic  signal  transduction  and  sensitivity/resistance  of  tumor  cells  to  TRAIL-induced 
apoptosis. Some antitumor agents have been shown to increase expression of death receptors 
at the level of transcription, translation or posttranslational modifications. This increase may 
result in enhanced sensitivity to TRAIL, while evidence exists that in some models cisplatin 
enhanced TRAIL-induced apoptosis without modulation of DRs expression [51,52]. Cisplatin 
has been shown to increase expression of TRAIL receptors DR4 or DR5 in esophageal and 
osteosarcoma tumor cells at the mRNA level [19,20]. Various mechanisms of regulation of 
DRs by chemotherapeutic drugs have been suggested. In addition to p53, other transcription 
factors such as NF-?B or Sp-1 have been demonstrated to be involved in the regulation of 
DR5 expression [53,54]. In our study, cisplatin as well as Pt(IV) complex LA-12 increased 
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the expression of DR5 mRNA and protein, and enhanced its surface level in colon but not in 
prostate carcinoma cells.  At the same time,  these agents were not effective in modulating 
DR4. The precise mechanisms responsible for cisplatin/LA-12-mediate increase of the DR5 
level in HCT-116 cells remain yet to be fully elucidated. We confirmed a functional role of 
DR5 in LA-12/cisplatin-mediated enhancement of TRAIL-induced apoptosis in colon cancer 
cells by showing that siRNA-mediated silencing of the DR5 surface level rescued cells from 
activation of caspase-8 and apoptosis induced by combination treatment.  This implies that 
DR5 plays  an important role in cisplatin/LA-12-mediated enhancement of TRAIL-induced 
apoptosis, being more important than DR4.
Localization  of  TRAIL  receptor  complexes  in  the  plasma  membrane  and  their 
distribution in membrane microdomains can have a significant functional impact on TRAIL 
signaling. Cisplatin has been shown to relocalize Fas receptors to lipid rafts and to enhance 
receptor clustering and apoptosis [55]. The shift of DR receptors to lipid rafts facilitated the 
apoptotic  outcome  of  TRAIL by depsipeptide,  quercetin,  and  oxaliplatin  [21,22,56].  LA-
12/cisplatin-mediated  relocalization  of  DR4  and  DR5  to  lipid  microdomains  was  also 
observed in our models of colon and prostate carcinoma cells. We suggest that in addition to 
the increase in surface DR levels, changes in lipid rafts localization of DR4 and DR5 may be 
important in LA-12/cisplatin-mediated reinforcement of TRAIL-induced apoptosis.
After the binding of death ligands to its cognate death receptors, complexes of ligand 
and membrane receptors can be internalized via endocytosis. Internalization of Fas receptor 
(CD95) has been shown to be crucial for Fas ligand-mediated formation of the DISC complex 
and induction of apoptosis. Inhibition of Fas internalization activated the prosurvival ERK 
and NF-?B signaling pathways [17]. The role  of internalization of the TRAIL ligand and 
receptor  complex  for  TRAIL-induced  apoptosis  has  not  been  fully  resolved  yet. 
Internalization was described not to influence formation of DISC and activation of caspase-8 
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in  a  type  I  BJAB Burkitt  lymphoma  B cell  line  [18].  Nevertheless,  transit  of  TRAIL to 
lysosomes was shown to contribute to TRAIL-induced apoptosis in the type II hepatocellular 
carcinoma cell line Huh-7 [57], and to participate in the activation of the lysosomal pathway 
of apoptosis. Internalization of TRAIL led to release of cathepsin B from lysosomes,  and 
liberalization of cytochrome c from mitochondria [58]. Here we demonstrated that cisplatin 
and  LA-12-mediated  enhancement  of  TRAIL-induced  apoptosis  was  accompanied  by 
accelerated internalization of TRAIL, suggesting its possible role in the effects observed. 
We demonstrated that cisplatin- and the novel platinum(IV) complex LA-12-mediated 
enhancement of TRAIL-induced apoptosis in human colon and prostate carcinoma cells were 
associated  with modulation  of  upstream events  of TRAIL signaling.  Cisplatin  and LA-12 
increased the expression of DR5, stimulated the relocalization of DR4 and DR5 to lipid rafts, 
and accelerated the internalization of TRAIL. Furthermore,  these drugs enhanced TRAIL-
induced caspase-8 activation, cleavage of caspase-3 and its substrate PARP and, overall, the 
fraction of apoptotic cells. We demonstrated a functional role of DR5 in the reinforcement of 
TRAIL-activated  apoptosis  by  cisplatin  and  LA-12.  Our  results  show  the  complexity  of 
interactions of signaling pathways triggered by TRAIL and cisplatin or LA-12, and highlight 
the striking ability of LA-12 to sensitize the cancer cells to TRAIL-induced apoptosis even 
when applied in significantly lower doses compared to cisplatin. Our observation will help to 
improve  therapeutical  approaches  to  cancer  diseases  in  terms  of  more  efficient  killing  of 
cancer cells, while minimizing the side effects of the therapy. 
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Legends to Figures
Figure  1 Pretreatment  of  HCT-116  and  PC-3  cells  with  cisplatin  or  LA-12  intensified 
cytotoxic effects of TRAIL. (a, b, e, f) WST test was performed in HCT-116 (a, b) and PC-3 
(e, f) cell lines pretreated with LA-12 (0.5 μM) (a, e) or cisplatin (10 μM) (b, f) for 24 h, and 
then  treated  with  TRAIL  (6.25-100  ng/ml)  for  further  24  h.  The  ability  of  the  cells  to 
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transform WST reagent to soluble formazan salt was measured as relative absorbance using 
plate reader Fluostar. (c, d, g, h) Real-time measurement of TRAIL toxic effects in HCT-116 
(c, d) and PC-3 (g, h) cells pretreated (24 h) with vehicle, LA-12 (0.5 μM) (c, g) or cisplatin 
(10  μM)  (d,  h)  and then incubated  for  20 h with TRAIL, was performed employing  the 
xCELLigence  RTCA SP system as  described in  Materials  and Methods.  Time of TRAIL 
application is indicated by an arrow-head.
Figure 2 Subtoxic concentrations of cisplatin and LA-12 enhanced TRAIL-induced cleavage 
of caspase-8, -3, and PARP. HCT-116 (a) and PC-3 (b) cells were pretreated with LA-12 (0.5 
μM) or cisplatin (10 μM) for 24 h, and then treated (4 h) with TRAIL (5 ng/ml). Proteins were 
detected by Western blotting. An equal loading was verified using anti-β-actin antibody. The 
results are representative of three independent experiments.
Figure 3 Total and surface level of DR5 was augmented by LA-12 and cisplatin. HCT-116 
(a) and PC-3 cells (b) were untreated or treated (24 h) with LA-12 (0.1-1 μM) or cisplatin (1.5 
μM), incubated with specific FITC-conjugated antibodies (Alexis),  and analysis  of surface 
DR4 and DR5 was performed using flow cytometer. DR5 mRNA (c) in HCT-116 cells treated 
(4 h) with LA-12 (0.5 μM) or cisplatin (1.5 μM), was detected by qRT-PCR, and total protein 
level (d) of DR4 and DR5 in HCT-116 cells treated (24 h) with LA-12 (0.5 μM) or cisplatin 
(1.5 and 10 μM) was detected by Western blotting.
 
Figure 4 Cisplatin and LA-12 treatment increased colocalization of TRAIL DR4 and DR5 
receptors with GM1-rich domains of plasma membrane. HCT-116 (a, b, c, d) and PC-3 (e) 
cells were incubated (1 h) with cisplatin (10 μM) or LA-12 (0.5 μM), cell surface receptors 
(green) and GM1-rich lipid rafts (blue) were labeled, detected by CLSM, and differences in 
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the  cross-correlation  coefficient  were noted  (p<0.005).  An example  is  shown for  DR5 in 
HCT-116 cells (a, b, c, fields of view: 5x5 μm). Confocal optical sections of 1.5 μm in size 
were  used  to  calculate  cross-correlation  of  cell  surface  receptors  and  GM1-rich  lipid 
microdomains for HCT-116 (d) and PC-3 (e) cells. Data are averages of the cross-correlation 
coefficient ± SEM of 40~60 independent measurements, normalized to control values.
Figure 5 Internalization of TRAIL is accelerated by platinum complexes cisplatin and LA-12. 
Cells were pretreated (24 h) with cisplatin (10 µM) and LA-12 (0.5 µM), and incubated with 
Alexa Fluor 647-conjugated TRAIL for 5 to 30 min. Simultaneously with TRAIL, 0.25 M 
sucrose was added to suppress endocytosis in appropriate samples. Flow cytometric analysis 
was accomplished. The amount of internalized TRAIL was expressed as percent of maximum 
fluorescence measured after 30 min of TRAIL incubation in HCT-116 (a) and PC-3 cells (b).
Figure  6 siRNA-mediated  silencing  of  DR5  prevented  enhancement  of  TRAIL-induced 
apoptosis by cisplatin and LA-12 in HCT-116 cells. (a) Surface DR5 level in HCT-116 cells 
with Lipofectamine alone or transfected (24 h) with control or DR5 siRNA (40 nM), followed 
by 24 h of incubation with cisplatin  (10  μM) or LA-12 (0.5  μM), was evaluated by flow 
cytometry (specific anti-DR5 PE-conjugated antibody,  Exbio). (b, c) Activity of caspase-8 
was measured by fluorogenic assay (b), and cleavage of caspase-8, PARP, and lamin B (c) in 
HCT-116 cells transfected (24 h) with control or DR5 siRNA (40 nM), then treated (24 h) 
with cisplatin (10 μM) or LA-12 (0.5 μM), and subsequently incubated (1 h) with TRAIL (5 
ng/ml), was detected by Western blotting. An equal loading was verified using anti-β-actin 
antibody.  The  results  are  representative  of  three  independent  experiments.  (d) Real-time 
measurement  of  TRAIL toxic  effects  in  HCT-116  cells  transfected  with  control  or  DR5 
siRNA, pretreated (24 h) with vehicle  or LA-12 (0.5  μM), and then incubated (4 h) with 
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TRAIL (50 ng/ml) was performed employing the xCELLigence RTCA SP system. Time of 
TRAIL application is indicated by an arrow-head. Data were normalized to the time interval 
when TRAIL treatment was performed (normalized cell index).
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